ABOUT US
COMPANY PROFILE
Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the
treatment of cardiovascular disease. Amarin's lead candidate, AMR101, was studied in two
concurrently run pivotal Phase 3 trials, MARINE and ANCHOR. These trials investigated the
efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides
(>500mg/dl) and in patients with mixed dyslipidemia who are taking statins, respectively.
Both trials are complete and the primary endpoints of both trials were met. In September 2011,
Amarin submitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)
seeking approval for the marketing and sale of AMR101 for treatment of patients with very high
triglycerides. The submission is based on the entire data set from the Company’s AMR101
development program, including safety and efficacy data from the Phase 3 MARINE and ANCHOR
studies.
Amarin's cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease.
Amarin is headquartered in Dublin, Ireland, and has its U.S. offices in Bedminster, New Jersey (headquarters) and Mystic, Connecticut. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN).
More Information: Download Company Profile
This page was last updated October 13, 2011.
Amarin's cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease.
Amarin is headquartered in Dublin, Ireland, and has its U.S. offices in Bedminster, New Jersey (headquarters) and Mystic, Connecticut. Amarin is listed in the U.S. on NASDAQ (ticker: AMRN).
More Information: Download Company Profile
This page was last updated October 13, 2011.